Abstract | OBJECTIVE: To determine if patients with diabetes mellitus taking a thiazolidinedione experienced higher proportions of distal upper and lower limb fractures compared with those not taking a thiazolidinedione, as recent US Food and Drug Administration safety alerts suggested. STUDY DESIGN: This 3-year cross-sectional study used medical and pharmacy claims from a large southeastern managed care organization for continuously enrolled members from January 1, 2004, through December 31, 2006. METHODS: RESULTS: The mean (SE) fracture proportions were significantly higher for thiazolidinedione users (5.1% [0.5%]) versus nonusers (4.5% [0.3%]) (P = .03). Fracture proportions did not differ by thiazolidinedione type (P = .86). Overall, women experienced a higher mean (SE) proportion of fractures compared with men (6.0% [0.4%] vs 3.5% [0.3%]) (P <.001), regardless of thiazolidinedione use. On average, the odds of experiencing a fracture for women using a thiazolidinedione increased 2% for every year increase in age. CONCLUSIONS: Patients with diabetes using thiazolidinediones, regardless of type, had higher proportions of distal upper and lower limb fractures compared with those not using thiazolidinediones. Fracture proportions were higher among women and increased with age.
|
Authors | Stephen G Jones, Soyal R Momin, Matthew W Good, Terence K Shea, Kenneth Patric |
Journal | The American journal of managed care
(Am J Manag Care)
Vol. 15
Issue 8
Pg. 491-6
(Aug 2009)
ISSN: 1936-2692 [Electronic] United States |
PMID | 19670952
(Publication Type: Journal Article)
|
Chemical References |
- Hypoglycemic Agents
- Thiazolidinediones
|
Topics |
- Arm Injuries
- Cross-Sectional Studies
- Diabetes Complications
- Diabetes Mellitus, Type 2
(drug therapy)
- Female
- Fractures, Bone
(chemically induced)
- Humans
- Hypoglycemic Agents
(adverse effects, therapeutic use)
- Insurance Claim Review
- Leg Injuries
- Logistic Models
- Male
- Managed Care Programs
(economics)
- Middle Aged
- Risk Assessment
- Sex Distribution
- Thiazolidinediones
(adverse effects, therapeutic use)
|